Abstract

The cell-envelope of Gram-negative bacteria contains endotoxic lipopolysaccharides (LPS) that are recognized by the innate immune system via Toll-Like Receptors (TLRs). The intestinal mucosal symbiont Akkermansia muciniphila is known to confer beneficial effects on the host and has a Gram-negative architecture. Here we show that A. muciniphila LPS lacks the O-polysaccharide repeating unit, with the resulting lipooligosaccharide (LOS) having unprecedented structural and signaling properties. The LOS consists of a complex glycan chain bearing two distinct undeca- and hexadecasaccharide units each containing three 2-keto-3-deoxy-D-manno-octulosonic acid (Kdo) residues. The lipid A moiety appears as a mixture of differently phosphorylated and acylated species and carries either linear or branched acyl moieties. Peritoneal injection of the LOS in mice increased higher gene expression of liver TLR2 than TLR4 (100-fold) and induced high IL-10 gene expression. A. muciniphila LOS was found to signal both through TLR4 and TLR2, whereas lipid A only induced TLR2 in a human cell line. We propose that the unique structure of the A. muciniphila LOS allows interaction with TLR2, thus generating an anti-inflammatory response as to compensate for the canonical inflammatory signaling associated with LOS and TLR4, rationalizing its beneficial host interaction.

Here, the authors characterize the structure of the Lipooligosaccharide of the gut symbiont Akkermansia muciniphila showing unique features and TLR4 and TLR2 signaling capacity, which underscore the beneficial properties of this bacterium.

Details

Title
The lipooligosaccharide of the gut symbiont Akkermansia muciniphila exhibits a remarkable structure and TLR signaling capacity
Author
Garcia-Vello, Pilar 1   VIAFID ORCID Logo  ; Tytgat, Hanne L. P. 2   VIAFID ORCID Logo  ; Elzinga, Janneke 3   VIAFID ORCID Logo  ; Van Hul, Matthias 4 ; Plovier, Hubert 4 ; Tiemblo-Martin, Marta 1 ; Cani, Patrice D. 5   VIAFID ORCID Logo  ; Nicolardi, Simone 6   VIAFID ORCID Logo  ; Fragai, Marco 7   VIAFID ORCID Logo  ; De Castro, Cristina 1   VIAFID ORCID Logo  ; Di Lorenzo, Flaviana 1 ; Silipo, Alba 8   VIAFID ORCID Logo  ; Molinaro, Antonio 8   VIAFID ORCID Logo  ; de Vos, Willem M. 9   VIAFID ORCID Logo 

 University of Naples Federico II, Department of Chemical Sciences, Napoli, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X) 
 Wageningen University, Laboratory of Microbiology, Wageningen, The Netherlands (GRID:grid.4818.5) (ISNI:0000 0001 0791 5666); Société des Produits Nestlé S.A., Nestlé Institute of Health Sciences, Nestlé Research, Lausanne, Switzerland (GRID:grid.419905.0) (ISNI:0000 0001 0066 4948) 
 Wageningen University, Laboratory of Microbiology, Wageningen, The Netherlands (GRID:grid.4818.5) (ISNI:0000 0001 0791 5666) 
 Université Catholique de Louvain, Louvain Drug Research Institute, Metabolism and Nutrition Research group, UCLouvain, Brussels, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X); 6, Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), WELBIO department, WEL Research Institute, avenue Pasteur, Wavre, Belgium (GRID:grid.509491.0) 
 Université Catholique de Louvain, Louvain Drug Research Institute, Metabolism and Nutrition Research group, UCLouvain, Brussels, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X); 6, Walloon Excellence in Life Sciences and BIOtechnology (WELBIO), WELBIO department, WEL Research Institute, avenue Pasteur, Wavre, Belgium (GRID:grid.509491.0); Université catholique de Louvain, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium (GRID:grid.7942.8) (ISNI:0000 0001 2294 713X) 
 Leiden University Medical Center, Center for Proteomics and Metabolomics, Leiden, The Netherlands (GRID:grid.10419.3d) (ISNI:0000 0000 8945 2978) 
 University of Florence, Magnetic Resonance Center (CERM), CIRMMP and Department of Chemistry “Ugo Schiff”, Florence, Italy (GRID:grid.8404.8) (ISNI:0000 0004 1757 2304) 
 University of Naples Federico II, Department of Chemical Sciences, Napoli, Italy (GRID:grid.4691.a) (ISNI:0000 0001 0790 385X); Osaka University, Department of Chemistry, School of Science, Osaka, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971) 
 Wageningen University, Laboratory of Microbiology, Wageningen, The Netherlands (GRID:grid.4818.5) (ISNI:0000 0001 0791 5666); University of Helsinki, Human Microbiome Research Program, Faculty of Medicine, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071) 
Pages
8411
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3110560397
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.